Genetic Net Receivables vs Long Term Debt Analysis

GENE Stock

USD 0.77 0.00 0.00%

Genetic Technologies financial indicator trend analysis is much more than just examining Genetic Technologies latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Genetic Technologies is a good investment. Please check the relationship between Genetic Technologies Net Receivables and its Long Term Debt accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.

Net Receivables vs Long Term Debt

Net Receivables vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Genetic Technologies Net Receivables account and Long Term Debt. At this time, the significance of the direction appears to have very week relationship.

The correlation between Genetic Technologies' Net Receivables and Long Term Debt is 0.27. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Genetic Technologies, assuming nothing else is changed. The correlation between historical values of Genetic Technologies' Net Receivables and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Genetic Technologies are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Net Receivables i.e., Genetic Technologies' Net Receivables and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.27

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Net Receivables

Long Term Debt

Long-term debt is a debt that Genetic Technologies has held for over one year. Long-term debt appears on Genetic Technologies balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Genetic Technologies balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Genetic Technologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Genetic Technologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.Tax Provision is expected to grow at the current pace this year, whereas Selling General Administrative is forecasted to decline to about 6.2 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	578.7K	676.6K	534.9K	488.7K
Interest Income	36.3K	220.2K	119.5K	74.3K

Reconciled Depreciation Interest Income

Genetic Technologies fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Inventory	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Long Term Debt
Total Assets		0.12	-0.14	0.98	0.81	-0.9	-0.09	0.9	0.18	-0.32	0.9	-0.08	0.3	0.05	-0.1	0.55	-0.05	0.31	0.94	0.33	-0.31	0.08	-0.19	-0.12	-0.27	-0.15
Other Current Liab	0.12		0.69	-0.01	0.43	0.19	-0.32	-0.17	0.55	-0.63	-0.17	-0.29	0.36	0.51	0.07	-0.16	0.71	0.86	-0.08	0.36	0.32	0.68	0.35	0.01	0.65	-0.08
Total Current Liabilities	-0.14	0.69		-0.31	0.13	0.41	-0.55	-0.38	0.46	-0.42	-0.38	-0.29	0.3	0.8	-0.19	-0.21	0.7	0.79	-0.31	0.32	0.39	0.89	0.81	-0.24	0.76	-0.03
Total Stockholder Equity	0.98	-0.01	-0.31		0.74	-0.94	0.0	0.93	0.09	-0.23	0.93	-0.1	0.24	-0.07	-0.05	0.57	-0.23	0.16	0.95	0.26	-0.43	-0.06	-0.3	-0.06	-0.4	-0.19
Property Plant And Equipment Net	0.81	0.43	0.13	0.74		-0.55	-0.07	0.57	0.56	-0.52	0.57	-0.1	0.23	0.12	-0.07	0.29	0.28	0.57	0.62	0.26	-0.02	0.26	-0.13	-0.11	0.05	0.1
Net Debt	-0.9	0.19	0.41	-0.94	-0.55		0.16	-1.0	0.23	0.19	-1.0	-0.04	-0.38	0.09	0.26	-0.62	0.32	0.0	-0.98	-0.4	0.49	0.16	0.31	0.25	0.6	0.34
Retained Earnings	-0.09	-0.32	-0.55	0.0	-0.07	0.16		-0.18	0.23	0.58	-0.18	0.09	-0.88	-0.77	0.71	-0.22	-0.36	-0.55	-0.17	-0.91	0.05	-0.68	-0.57	0.72	-0.09	0.54
Cash	0.9	-0.17	-0.38	0.93	0.57	-1.0	-0.18		-0.23	-0.2	1.0	0.08	0.4	-0.07	-0.28	0.63	-0.25	0.03	0.99	0.42	-0.43	-0.13	-0.29	-0.28	-0.57	-0.32
Non Current Assets Total	0.18	0.55	0.46	0.09	0.56	0.23	0.23	-0.23		-0.3	-0.23	-0.24	-0.23	0.11	0.2	-0.25	0.43	0.52	-0.17	-0.22	0.37	0.33	0.08	0.15	0.58	0.58
Non Currrent Assets Other	-0.32	-0.63	-0.42	-0.23	-0.52	0.19	0.58	-0.2	-0.3		-0.2	0.02	-0.6	-0.36	0.44	0.07	-0.47	-0.67	-0.22	-0.65	0.0	-0.48	-0.05	0.49	-0.18	0.22
Cash And Short Term Investments	0.9	-0.17	-0.38	0.93	0.57	-1.0	-0.18	1.0	-0.23	-0.2		0.08	0.4	-0.07	-0.28	0.63	-0.25	0.02	0.99	0.42	-0.43	-0.14	-0.29	-0.28	-0.57	-0.31
Net Receivables	-0.08	-0.29	-0.29	-0.1	-0.1	-0.04	0.09	0.08	-0.24	0.02	0.08		-0.01	-0.46	-0.34	-0.31	0.21	-0.37	0.01	-0.02	0.22	-0.49	-0.43	-0.33	-0.2	0.27
Common Stock Total Equity	0.3	0.36	0.3	0.24	0.23	-0.38	-0.88	0.4	-0.23	-0.6	0.4	-0.01		0.55	-0.68	0.31	0.35	0.53	0.38	0.99	-0.15	0.48	0.3	-0.69	0.02	-0.5
Common Stock Shares Outstanding	0.05	0.51	0.8	-0.07	0.12	0.09	-0.77	-0.07	0.11	-0.36	-0.07	-0.46	0.55		-0.2	0.24	0.44	0.75	0.01	0.58	0.04	0.95	0.89	-0.23	0.47	-0.42
Inventory	-0.1	0.07	-0.19	-0.05	-0.07	0.26	0.71	-0.28	0.2	0.44	-0.28	-0.34	-0.68	-0.2		-0.14	-0.21	-0.11	-0.17	-0.7	-0.13	-0.14	-0.05	1.0	0.24	0.04
Other Stockholder Equity	0.55	-0.16	-0.21	0.57	0.29	-0.62	-0.22	0.63	-0.25	0.07	0.63	-0.31	0.31	0.24	-0.14		-0.23	-0.01	0.64	0.32	-0.16	0.13	-0.01	-0.11	-0.4	-0.2
Total Liab	-0.05	0.71	0.7	-0.23	0.28	0.32	-0.36	-0.25	0.43	-0.47	-0.25	0.21	0.35	0.44	-0.21	-0.23		0.66	-0.2	0.34	0.63	0.55	0.39	-0.25	0.68	0.26
Property Plant And Equipment Gross	0.31	0.86	0.79	0.16	0.57	0.0	-0.55	0.03	0.52	-0.67	0.02	-0.37	0.53	0.75	-0.11	-0.01	0.66		0.12	0.55	0.08	0.87	0.58	-0.18	0.63	-0.22
Total Current Assets	0.94	-0.08	-0.31	0.95	0.62	-0.98	-0.17	0.99	-0.17	-0.22	0.99	0.01	0.38	0.01	-0.17	0.64	-0.2	0.12		0.4	-0.45	-0.04	-0.22	-0.18	-0.48	-0.36
Common Stock	0.33	0.36	0.32	0.26	0.26	-0.4	-0.91	0.42	-0.22	-0.65	0.42	-0.02	0.99	0.58	-0.7	0.32	0.34	0.55	0.4		-0.15	0.51	0.3	-0.71	-0.02	-0.52
Short Long Term Debt Total	-0.31	0.32	0.39	-0.43	-0.02	0.49	0.05	-0.43	0.37	0.0	-0.43	0.22	-0.15	0.04	-0.13	-0.16	0.63	0.08	-0.45	-0.15		0.12	0.1	-0.13	0.29	0.66
Other Current Assets	0.08	0.68	0.89	-0.06	0.26	0.16	-0.68	-0.13	0.33	-0.48	-0.14	-0.49	0.48	0.95	-0.14	0.13	0.55	0.87	-0.04	0.51	0.12		0.83	-0.19	0.61	-0.3
Short Term Debt	-0.19	0.35	0.81	-0.3	-0.13	0.31	-0.57	-0.29	0.08	-0.05	-0.29	-0.43	0.3	0.89	-0.05	-0.01	0.39	0.58	-0.22	0.3	0.1	0.83		-0.08	0.58	-0.32
Intangible Assets	-0.12	0.01	-0.24	-0.06	-0.11	0.25	0.72	-0.28	0.15	0.49	-0.28	-0.33	-0.69	-0.23	1.0	-0.11	-0.25	-0.18	-0.18	-0.71	-0.13	-0.19	-0.08		0.18	0.04
Accounts Payable	-0.27	0.65	0.76	-0.4	0.05	0.6	-0.09	-0.57	0.58	-0.18	-0.57	-0.2	0.02	0.47	0.24	-0.4	0.68	0.63	-0.48	-0.02	0.29	0.61	0.58	0.18		0.18
Long Term Debt	-0.15	-0.08	-0.03	-0.19	0.1	0.34	0.54	-0.32	0.58	0.22	-0.31	0.27	-0.5	-0.42	0.04	-0.2	0.26	-0.22	-0.36	-0.52	0.66	-0.3	-0.32	0.04	0.18

Click cells to compare fundamentals

Genetic Technologies Account Relationship Matchups

Genetic Technologies fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.6M	23.0M	20.8M	14.9M	6.2M	5.9M
Other Current Liab	806.5K	956.1K	2.4M	2.2M	1.9M	1.1M
Total Current Liabilities	1.4M	1.4M	3.8M	3.3M	4.2M	4.4M
Total Stockholder Equity	13.0M	21.5M	16.4M	11.2M	1.8M	1.7M
Property Plant And Equipment Net	440.2K	637.7K	953.3K	599.2K	264.5K	251.3K
Net Debt	(13.7M)	(20.7M)	(11.1M)	(7.3M)	(145.4K)	(152.7K)
Retained Earnings	(135.9M)	(143.1M)	(150.2M)	(156.7M)	(166.4M)	(158.1M)
Cash	14.2M	20.9M	11.7M	7.9M	1.0M	969.6K
Non Current Assets Total	440.2K	735.6K	6.1M	4.4M	2.5M	2.4M
Non Currrent Assets Other	(440.2K)	97.9K	(6.1M)	(4.2M)	81.7K	154.1K
Cash And Short Term Investments	14.2M	20.9M	11.7M	7.9M	1.0M	987.4K
Net Receivables	789.4K	89.5K	442.2K	191.9K	209.3K	198.8K
Common Stock Total Equity	122.4M	125.5M	140.1M	153.6M	176.6M	89.1M
Common Stock Shares Outstanding	41.6M	85.4M	92.2M	101.4M	132.2M	138.8M
Liabilities And Stockholders Equity	15.6M	23.0M	20.8M	14.9M	6.2M	5.9M
Inventory	91.4K	76.9K	398.2K	325.9K	206.5K	196.1K
Other Stockholder Equity	13.0M	162.0M	11.5M	6.5M	7.5M	7.1M
Total Liab	2.6M	1.4M	4.4M	3.7M	4.4M	2.4M
Property Plant And Equipment Gross	440.2K	637.7K	1.9M	1.8M	1.5M	925.5K
Total Current Assets	15.2M	22.2M	14.7M	10.5M	3.7M	3.5M
Common Stock	140.1M	153.6M	155.1M	161.3M	163.8M	98.7M
Short Long Term Debt Total	481.8K	204.0K	652.5K	532.8K	875.2K	918.9K
Other Current Assets	97.8K	1.2M	2.1M	2.1M	2.2M	2.4M
Short Term Debt	240.9K	179.6K	264.1K	303.6K	852.3K	894.9K
Accounts Payable	350.2K	269.7K	1.2M	838.0K	1.5M	895.2K
Short Term Investments	2.0K	1.9K	13.3K	17.4K	18.8K	17.9K
Property Plant Equipment	440.2K	637.7K	953.3K	599.2K	539.3K	759.3K
Non Current Liabilities Total	1.2M	33.3K	558.9K	381.6K	160.6K	152.6K
Accumulated Other Comprehensive Income	8.8M	11.0M	11.5M	6.5M	4.4M	4.5M
Other Liab	979.2K	8.9K	170.5K	152.3K	175.2K	128.6K
Net Tangible Assets	13.0M	21.5M	11.3M	7.5M	8.7M	10.6M
Capital Lease Obligations	429.5K	204.0K	652.5K	532.8K	231.6K	205.1K
Net Invested Capital	13.1M	21.5M	16.4M	11.2M	2.5M	2.4M
Net Working Capital	13.8M	20.8M	10.9M	7.2M	(500.1K)	(475.1K)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Genetic Technologies is a strong investment it is important to analyze Genetic Technologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Genetic Technologies' future performance. For an informed investment choice regarding Genetic Stock, refer to the following important reports:

How To Invest In Genetic

Details

Is Genetic Stock a good investment?

Details

What is Genetic Technologies' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.

You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.02)

Revenue Per Share

2.19

Quarterly Revenue Growth

(0.11)

Return On Assets

(0.63)

Return On Equity

(1.85)

The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Genetic Net Receivables vs Long Term Debt Analysis

Net Receivables vs Long Term Debt

Net Receivables vs Long Term Debt Correlation Analysis

Correlation Coefficient

Net Receivables

Long Term Debt

Genetic Technologies fundamental ratios Correlations

Genetic Technologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Genetic Technologies fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Intangible Assets	+ 1.0	Inventory
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Common Stock	+ 0.99	Common Stock Total Equity
Total Stockholder Equity	+ 0.98	Total Assets

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.94	Total Stockholder Equity
Common Stock	- 0.91	Retained Earnings
Net Debt	- 0.9	Total Assets